SEC Form 4 · accession 0001144204-17-058402
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert G L Shorr
Director
Period of report
Nov 10, 2017
Accepted (ET)
Nov 13, 2017 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 10, 2017 | A | 8,666 | $0.00 | A | 45,731 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired are shares of restricted stock awarded on November 10, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.